Physician profile
Paul D Chambliss
NPI 1841251980
$4,122.32
in general payments reported to CMS, 2019-2025
15 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $630 · 2021: $600 · 2022: $125 · 2023: $400 · 2024: $292 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,467.18 | 2019-2025 | Apretude |
| Gilead Sciences, INC. | $1,111.14 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $328.25 | 2019-2021 | |
| Hologic Sales and Service, LLC | $237.19 | 2023 | Aptima |
| Abbvie INC. | $233.18 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $199.19 | 2019 | |
| Janssen Biotech, INC. | $167.07 | 2019-2020 | |
| Theratechnologies INC. | $123.69 | 2019 | |
| Emd Serono, INC. | $97.53 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $71.13 | 2019 | |
| Janssen Products, LP | $19.98 | 2019 | |
| Indivior INC. | $19.00 | 2019 | |
| Orexo US, INC. | $16.53 | 2019 | |
| Glaxosmithkline, LLC. | $16.34 | 2021 | |
| Seqirus USA INC | $14.92 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chambliss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.